*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Kaisa Health Group Holdings Limited**
**佳兆業健康集團控股有限公司**
*(Incorporated in Bermuda with limited liability)*
**(Stock Code: 876)**

# SUPPLEMENTAL ANNOUNCEMENT TO 2023 ANNUAL REPORT

Reference is made to the annual report for the year ended 31 December 2023 published by Kaisa Health Group Holdings Limited (the "**Company**") on 29 April 2024 (the "**Annual Report**"). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Annual Report. This announcement provides supplemental information to the Annual Report and should be read in conjunction with the Annual Report.

**Use of proceeds from the Rights Issue during the year ended 31 December 2023**

As set out on page 74 of the Annual Report, the net proceeds from the Rights Issue of HK$507.16 million was fully utilized as at the date of the Annual Report, as to (i) approximately HK$246 million for investments within the health care industry in the PRC, (ii) approximately HK$164.16 million for seeking suitable investment opportunities, and (iii) approximately HK$97 million for the continuous development of dental business. The net proceeds from the Rights Issue had been utilized in accordance with the usage and allocation as previously disclosed.

The net proceeds from the Rights Issue of HK$507.16 million had been used between 2019 and 2023, of which approximately HK$5,050,000 had been used during the year ended 31 December 2023 for the continuous development of dental business. The Company would like to provide further information on the breakdown and description of the proceeds and the purpose for which the proceeds were used during the year ended 31 December 2023 are set out below:

| **Purpose** | **Amount** *(HK$'000)* |
|---|---|
| Operating cost of dental business | 3,196 |
| Product research and development expenses for dental business | 1,604 |
| Marketing and promotion expenses | 250 |
| **Total** | **5,050** |

**Significant Investments**

The Company would like to clarify two inadvertent clerical errors in the column headed "Percentage of fair value relative to total assets" of the table relating to the Company's significant investments on page 12 of the Annual Report. The Company had significant investments in Zhuhai Jinyiming Equity Investment Fund Partnership (L.P.) and Haoyi Healthcare Services (Shenzhen) Partnership (Limited Partnership) with fair value of HK$144 million and HK$49.1 million respectively, representing about 23.8% (instead of 74.6%) and 8.1% (instead of 25.4%) of the Group's total assets as at 31 December 2023.

The information contained in this supplemental announcement does not affect the other information contained in the Annual Report. Save as disclosed in this announcement, all the other information and contents in the Annual Report remain unchanged.

By order of the Board
**Kaisa Health Group Holdings Limited**
**Kwok Ying Shing**
*Chairman and Executive Director*

Hong Kong, 2 August 2024

*As at the date of this announcement, the Board comprises Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun as executive Directors; and Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying as independent non-executive Directors.*